Jonathan Zalevsky, Chief R&D Officer at NEKTAR THERAPEUTICS (NKTR), sold 51,115 shares at $0.94 ($48K) on 2024-12-19, disclosed to the SEC on 2024-12-20.
Seasonal sale ($48k) by Chief R&D Officer — this insider has traded NKTR in December in at least three consecutive prior years. Pattern-driven, low signal.
Negative factors outweigh the positive ones.
| Filing → |
| NKTR | SELL | 2026-06-17 | $336K | — | Filing → |
| NKTR | SELL | 2026-05-21 | $13K | — | Filing → |
| NKTR | SELL | 2026-02-20 | $13K | — | Filing → |